Gilead Sciences Inc (NAS:GILD) Stock News, Headlines & Updates
Gilead Sciences Inc Stock News from GuruFocus
- 1
Aug 27, 2024
“The Adventure Jar,” Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together
ACCESSWIRE • 11:00am
Aug 21, 2024
Gilead Sciences to Present at Upcoming Investor Conferences
Business Wire • 4:00pm
Aug 20, 2024
Gilead Sciences: "One of Best Employers for Women" by Forbes
ACCESSWIRE • 11:00am
Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences
ACCESSWIRE • 11:00am
Aug 14, 2024
Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 3:01pm
Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
Business Wire • 1:00pm
Aug 13, 2024
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
ACCESSWIRE • 11:00am
Aug 09, 2024
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus Research • 11:12pm
Aug 08, 2024
Gilead Sciences Announces Second Quarter 2024 Financial Results
Business Wire • 4:00pm
Gilead Sciences (GILD) Q2 2024 Earnings: EPS of $1.29 Beats Estimates, Revenue Hits $7.0 Billion
GuruFocus Research • 3:51pm
Closing the HIV Diagnosis Gap in Germany with Gilead Sciences
ACCESSWIRE • 11:00am
Aug 07, 2024
Gilead Sciences Inc (GILD) Q2 2024: Everything You Need To Know Ahead Of Earnings
GuruFocus Research • 7:01am
Jul 25, 2024
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Business Wire • 4:00pm
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Business Wire • 9:00am
Jul 24, 2024
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
Business Wire • 4:00am
Jul 22, 2024
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
Business Wire • 4:00am
Jul 17, 2024
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
Business Wire • 8:00am
Jul 16, 2024
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
Business Wire • 8:00am
Jul 02, 2024
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 1:17am
Jul 01, 2024
Gilead Benefit Helps Employees Navigate Cancer Care
ACCESSWIRE • 11:00am
Jun 20, 2024
Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
Business Wire • 8:00am
Jun 19, 2024
Gilead and Kite Pharma Celebrates Pride Month
ACCESSWIRE • 11:00am
Jun 14, 2024
Gilead Sciences Inc's Dividend Analysis
GuruFocus Research • 5:01am
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
Business Wire • 3:00am
Jun 12, 2024
How Luciana Preger Is Helping Advance Gilead's Work in Oncology
ACCESSWIRE • 11:00am
Jun 06, 2024
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
Business Wire • 4:00am
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 11:00pm
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 7:00pm
Jun 05, 2024
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 11:00am
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
Business Wire • 2:00am
Jun 03, 2024
Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Business Wire • 10:00am
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Business Wire • 9:00am
Jun 02, 2024
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Business Wire • 8:00am
Jun 01, 2024
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Business Wire • 8:00am
May 31, 2024
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
Business Wire • 8:00am
May 30, 2024
Gilead Provides Update on Phase 3 TROPiCS-04 Study
Business Wire • 4:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news